BUZZ-Corvus Pharma slips after launching $150 mln equity offering

Reuters01-21
BUZZ-Corvus Pharma slips after launching $150 mln equity offering

** Shares of Corvus Pharmaceuticals CRVS.O down 3.5% at $20.66 post-market as it seeks equity raise

** Biopharma firm commences $150 mln offering of stock and pre-funded warrants

** Co intends to use net offering proceeds for working capital and general purposes, including capex and R&D, including for its Phase 3 T cell lymphoma, and Phase 2 atopic dermatitis, hidradenitis suppurativa and asthma clinical trials

** CRVS shares on Tues soared 166% to close at about 7-yr high of $21.41 after co early Tues announced positive early-stage soquelitinib data for atopic dermatitis (eczema)

** Jefferies and Goldman Sachs are lead joint bookrunners for offering, joined by Mizuho

** South San Francisco, California-based CRVS has ~74.7 mln shares outstanding

** Stock gained 44% in 2025

** All 7 analysts are bullish on the stock; median PT $18, per LSEG data

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment